PDE10A is a class of phosphodiesterases that degrades cAMP and cGMP, molecules responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10A activity, levels of cAMP and cGMP are increased within neurons and the ability of these neurons to function properly is thereby improved.
PDE10A has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders, such as schizophrenia, Parkinson’s disease and obsessive compulsive disorder. PDE10A inhibitors may therefore be useful in treating these disorders.
Memory Pharmaceuticals has identified two lead chemical series of compounds that have demonstrated effectiveness in the selective inhibition of PDE10A activity. Representatives of these PDE10A inhibitors have been shown to be effective in several animal models of schizophrenia. The company is exploring partnership opportunities for this program.
“We believe PDE10A is a compelling target for novel antipsychotics and are pleased to formally announce the addition of this program to our pipeline,” said Memory Pharmaceuticals’ chief scientific officer, Dr David Lowe. “The advancement of this program is consistent with our mission to develop novel treatments for CNS disorders based on our extensive knowledge of and experience with a diverse set of pathways.”